Physiogenex will present at the EASL – International Liver Congress 2018 in Paris, on April the 12th, 2018.
Dr. François Briand, Director of Research and Business Development, will be presenting a poster (#THU-490 / session NAFLD) on Thursday, April the 12th, about the effects of obeticholic acid (OCA) and elafibranor (GFT505) in the Diet-Induced NASH (DIN) mouse and hamster models.
Looking forward to meet you there!
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications. We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We focus on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.
Please visit our website for more information